We won’t be told that details - we just have to make sure we have x amount of planes free
Maybe it’s the airlines bail out lol
Got something to say or just want fewer pesky ads? Join us... 😊
[News] The Coronavirus Good News thread
- Thread starter Bozza
- Start date
We won’t be told that details - we just have to make sure we have x amount of planes free
Maybe it’s the airlines bail out lol
15 minutes tests in boots today
£100 though!
Wouldn’t the gov be better paying for these if they work?
£100 though!
Wouldn’t the gov be better paying for these if they work?
beorhthelm
A. Virgo, Football Genius
- Jul 21, 2003
- 36,011
not at £100 a pop.
Won't bother copying and pasting the entire article (on the Mail Online) as it's largely pretty similar to a number others but Oxford Professor Adrian Hill who is involved with the trials has suggested the "unblinding is now imminent" on the initial Phase III trials, which makes me think the Oxford/AstraZeneca vaccine may win the race after all.
He also praises the MHRA and suggests they will move quicker than the FDA to approve for Emergency Use.
Medics and high-risk patients are likely to receive Oxford's Covid-19 vaccine before the end of the year, the professor leading the project said.
He also praises the MHRA and suggests they will move quicker than the FDA to approve for Emergency Use.
Medics and high-risk patients are likely to receive Oxford's Covid-19 vaccine before the end of the year, the professor leading the project said.
macbeth
Dismembered
LONDON (Reuters) - The COVID-19 vaccine being developed by the University of Oxford produces a similar immune response in both older and younger adults , and adverse responses were lower among the elderly, British drug maker AstraZeneca Plc (AZN.L) said on Monday.
A vaccine that works is seen as a game-changer in the battle against the novel coronavirus, which has killed more than 1.15 million people, hammered the global economy and shuttered normal life across the world.
"It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher," an AstraZeneca spokesman told Reuters.
The results further build the body of evidence for the safety and immunogenicity of AZD1222," the spokesman said, referring to the technical name of the vaccine.
The news that older people get an immune response from the vaccine is positive because the immune system weakens with age and older people are those most at risk of dying from the virus.
The Financial Times reported earlier that the vaccine, being developed by Oxford and AstraZeneca, triggers protective antibodies and T-cells in older age groups - among those most at risk from the virus.
The Oxford/AstraZeneca vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with Pfizer (PFE.N) and BioNTech's (22UAy.F) candidate.
If it works, a vaccine would allow the world to return to some measure of normality after the tumult of the pandemic.
Immunogenicity blood tests carried out on a subset of older participants echo data released in July which showed the vaccine generated "robust immune responses" in a group of healthy adults aged between 18 and 55, the Financial Times reported.
https://mobile.reuters.com/article/amp/idUSKBN27B0L7
A vaccine that works is seen as a game-changer in the battle against the novel coronavirus, which has killed more than 1.15 million people, hammered the global economy and shuttered normal life across the world.
"It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher," an AstraZeneca spokesman told Reuters.
The results further build the body of evidence for the safety and immunogenicity of AZD1222," the spokesman said, referring to the technical name of the vaccine.
The news that older people get an immune response from the vaccine is positive because the immune system weakens with age and older people are those most at risk of dying from the virus.
The Financial Times reported earlier that the vaccine, being developed by Oxford and AstraZeneca, triggers protective antibodies and T-cells in older age groups - among those most at risk from the virus.
The Oxford/AstraZeneca vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with Pfizer (PFE.N) and BioNTech's (22UAy.F) candidate.
If it works, a vaccine would allow the world to return to some measure of normality after the tumult of the pandemic.
Immunogenicity blood tests carried out on a subset of older participants echo data released in July which showed the vaccine generated "robust immune responses" in a group of healthy adults aged between 18 and 55, the Financial Times reported.
https://mobile.reuters.com/article/amp/idUSKBN27B0L7
Thanks for posting - I think one of the key parts is actually just a bit lower in the article;
"Details of the finding are expected to be published shortly in a clinical journal, the FT said. It did not name the publication."
So I assume this is a drip-feeding out of Oxford/AZ's initial Phase III efficacy data.
That’s....next week. Shit’s getting real.
driller
my life my word
Declining antibody levels do not mean less immunity, experts say. Besides, two widely used tests may detect the wrong antibodies.
Your blood carries the memory of every pathogen you’ve ever encountered. If you’ve been infected with the coronavirus, your body most likely remembers that, too.
Antibodies are the legacy of that encounter. Why, then, have so many people stricken by the virus discovered that they don’t seem to have antibodies?
Blame the tests.
Most commercial antibody tests offer crude yes-no answers. The tests are notorious for delivering false positives — results indicating that someone has antibodies when he or she does not.
But the volume of coronavirus antibodies drops sharply once the acute illness ends. Now it is increasingly clear that these tests may also produce false-negative results, missing antibodies to the coronavirus that are present at low levels.
Moreover, some tests — including those made by Abbott and Roche and offered by Quest Diagnostics and LabCorp — are designed to detect a subtype of antibodies that doesn’t confer immunity and may wane even faster than the kind that can destroy the virus.
What that means is that declining antibodies, as shown by commercial tests, don’t necessarily mean declining immunity, several experts said. Long-term surveys of antibodies, intended to assess how widely the coronavirus has spread, may also underestimate the true prevalence.
“We’re learning a lot about how antibodies change over time,” said Dr. Fiona Havers, a medical epidemiologist who has led such surveys for the Centers for Disease Control and Prevention.
If the narrative on immunity to the coronavirus has seemed to shift constantly, it’s in part because the virus was a stranger to scientists. But it’s increasingly clear that this virus behaves much like any other.
This is how immunity to viruses generally works: The initial encounter with a pathogen — typically in childhood — surprises the body. The resulting illness can be mild or severe, depending on the dose of the virus and the child’s health, access to health care and genetics.
A mild illness may trigger production of only a few antibodies, and a severe one many more. The vast majority of people who become infected with the coronavirus have few to no symptoms, many experts believe, and those people may produce a milder immune response.
But even a minor infection is often enough to teach the body to recognize the intruder.
“Whatever your level is today, if you get infected, your antibody titers are going to go way up,” said Dr. Michael Mina, an immunologist at Harvard University, referring to the levels of antibodies in the blood. “The virus will never even have a chance the second time around.”
A single drop of blood contains billions of antibodies, all lying in wait for their specific targets. Sometimes, as may be the case for antibodies to the coronavirus, there are too few to get a positive signal on a test — but that does not mean the person tested has no immunity to the virus.
“Even if their antibodies wane below the limits of detection of our instruments, it doesn’t mean their ‘memory’ is gone,” Dr. Mina said.
A small number of people may not produce any antibodies to the coronavirus. But even in that unlikely event, they will have so-called cellular immunity, which includes T cells that learn to identify and destroy the virus. Virtually everyone infected with the coronavirus seems to develop T-cell responses, according to several recent studies.
https://www.nytimes.com/2020/07/26/health/coronvirus-antibody-tests.html
Your blood carries the memory of every pathogen you’ve ever encountered. If you’ve been infected with the coronavirus, your body most likely remembers that, too.
Antibodies are the legacy of that encounter. Why, then, have so many people stricken by the virus discovered that they don’t seem to have antibodies?
Blame the tests.
Most commercial antibody tests offer crude yes-no answers. The tests are notorious for delivering false positives — results indicating that someone has antibodies when he or she does not.
But the volume of coronavirus antibodies drops sharply once the acute illness ends. Now it is increasingly clear that these tests may also produce false-negative results, missing antibodies to the coronavirus that are present at low levels.
Moreover, some tests — including those made by Abbott and Roche and offered by Quest Diagnostics and LabCorp — are designed to detect a subtype of antibodies that doesn’t confer immunity and may wane even faster than the kind that can destroy the virus.
What that means is that declining antibodies, as shown by commercial tests, don’t necessarily mean declining immunity, several experts said. Long-term surveys of antibodies, intended to assess how widely the coronavirus has spread, may also underestimate the true prevalence.
“We’re learning a lot about how antibodies change over time,” said Dr. Fiona Havers, a medical epidemiologist who has led such surveys for the Centers for Disease Control and Prevention.
If the narrative on immunity to the coronavirus has seemed to shift constantly, it’s in part because the virus was a stranger to scientists. But it’s increasingly clear that this virus behaves much like any other.
This is how immunity to viruses generally works: The initial encounter with a pathogen — typically in childhood — surprises the body. The resulting illness can be mild or severe, depending on the dose of the virus and the child’s health, access to health care and genetics.
A mild illness may trigger production of only a few antibodies, and a severe one many more. The vast majority of people who become infected with the coronavirus have few to no symptoms, many experts believe, and those people may produce a milder immune response.
But even a minor infection is often enough to teach the body to recognize the intruder.
“Whatever your level is today, if you get infected, your antibody titers are going to go way up,” said Dr. Michael Mina, an immunologist at Harvard University, referring to the levels of antibodies in the blood. “The virus will never even have a chance the second time around.”
A single drop of blood contains billions of antibodies, all lying in wait for their specific targets. Sometimes, as may be the case for antibodies to the coronavirus, there are too few to get a positive signal on a test — but that does not mean the person tested has no immunity to the virus.
“Even if their antibodies wane below the limits of detection of our instruments, it doesn’t mean their ‘memory’ is gone,” Dr. Mina said.
A small number of people may not produce any antibodies to the coronavirus. But even in that unlikely event, they will have so-called cellular immunity, which includes T cells that learn to identify and destroy the virus. Virtually everyone infected with the coronavirus seems to develop T-cell responses, according to several recent studies.
https://www.nytimes.com/2020/07/26/health/coronvirus-antibody-tests.html
They would do well to give the tests for free to those wanting to come for a holiday, foreign student, etc in the UK. Might cost a hundred quid but what they'll spend over a week or two weeks will more than compensate.
Oxford Covid vaccine works in all ages, trials suggest
https://www.theguardian.com/world/2...-astrazeneca-works-in-all-ages-trials-suggest
One of the world’s leading Covid-19 experimental vaccines produces an immune response in older adults as well as the young, its developers say, raising hopes of protection for those most vulnerable to the coronavirus that has caused social and economic chaos around the world.
Neither Oxford University nor its commercial partner AstraZeneca would release the data from the early trials showing the positive effects, which are being submitted to a peer-reviewed journal. But AstraZeneca confirmed the basic findings about the vaccine it calls AZD1222, which were shared at a closed academic meeting.
The phase 2 trials have shown that people over the age of 56 – and some over 70 – produced the same sort of antibody response as younger volunteers. Whether older people would be protected has always been a key question for the vaccines being developed. The body’s natural immune system and therefore its ability to fight any virus weakens with age, which is why the Covid death rate rises in older people.
The data also shows that fewer side-effects – referred to by the scientists as “reactogenicity” – were reported in the older volunteers, which is encouraging, although it could mean fewer of them reported issues such as a sore arm.
“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the Covid-19 disease severity is higher. The results further build the body of evidence for the safety and immunogenicity of AZD1222,” said an AstraZeneca spokesman.
A vaccine that works is seen as a game-changer in the battle against coronavirus, which has killed more than 1.15 million people, shuttered swathes of the global economy and turned normal life upside down for billions of people. However, few think the first vaccines will be fully protective. They may instead reduce the severity of illness, so that people avoid hospital and deaths are reduced. They may also not last, so that boosters will be needed.
AstraZeneca said it hoped the vaccine may be ready for limited use within the coming months. “We anticipate efficacy read-outs from phase 2/3 trials between now and the end of the year, and if approved within countries, doses of the potential vaccine could be available for use before the end of the year,” said the spokesperson.
https://www.theguardian.com/world/2...-astrazeneca-works-in-all-ages-trials-suggest
One of the world’s leading Covid-19 experimental vaccines produces an immune response in older adults as well as the young, its developers say, raising hopes of protection for those most vulnerable to the coronavirus that has caused social and economic chaos around the world.
Neither Oxford University nor its commercial partner AstraZeneca would release the data from the early trials showing the positive effects, which are being submitted to a peer-reviewed journal. But AstraZeneca confirmed the basic findings about the vaccine it calls AZD1222, which were shared at a closed academic meeting.
The phase 2 trials have shown that people over the age of 56 – and some over 70 – produced the same sort of antibody response as younger volunteers. Whether older people would be protected has always been a key question for the vaccines being developed. The body’s natural immune system and therefore its ability to fight any virus weakens with age, which is why the Covid death rate rises in older people.
The data also shows that fewer side-effects – referred to by the scientists as “reactogenicity” – were reported in the older volunteers, which is encouraging, although it could mean fewer of them reported issues such as a sore arm.
“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the Covid-19 disease severity is higher. The results further build the body of evidence for the safety and immunogenicity of AZD1222,” said an AstraZeneca spokesman.
A vaccine that works is seen as a game-changer in the battle against coronavirus, which has killed more than 1.15 million people, shuttered swathes of the global economy and turned normal life upside down for billions of people. However, few think the first vaccines will be fully protective. They may instead reduce the severity of illness, so that people avoid hospital and deaths are reduced. They may also not last, so that boosters will be needed.
AstraZeneca said it hoped the vaccine may be ready for limited use within the coming months. “We anticipate efficacy read-outs from phase 2/3 trials between now and the end of the year, and if approved within countries, doses of the potential vaccine could be available for use before the end of the year,” said the spokesperson.
Marshy
Well-known member
Operational update for BSUH
We are currently caring for 34 patients with COVID-19, 1 of whom is in critical care.
Although numbers still increasing, Only 1 in ITU.
We are currently caring for 34 patients with COVID-19, 1 of whom is in critical care.
Although numbers still increasing, Only 1 in ITU.
driller
my life my word
In preparation for the month long lock down, Mikkeller are selling all the contents of their Berlin bar at 50% discount. That’s draft, cans, bottles and even merch.
Anyone who knows anything about craft will know 50% off their prices is good news.
Never one to shirk my civic duties I’m confronting this head on.
I have also taken tomorrow off.
Come and get me Corona!
Anyone who knows anything about craft will know 50% off their prices is good news.
Never one to shirk my civic duties I’m confronting this head on.
I have also taken tomorrow off.
Come and get me Corona!
Yoda
English & European
SARS-CoV-2-specific T cell immunity found in cases of COVID-19 and SARS, and previously uninfected samples.
https://www.nature.com/articles/s41586-020-2550-z?flip=true
Short version: Brought to light by a recent video by Dr John Campbell, but a study published in July was showing people who were previously infected with the 2003 SARS virus are showing Memory T-Cell immunity 17 years after being infected with SARS-CoV-1 to SARS-CoV-2. They also tested 37 samples they had taken from uninfected people from 2019 (so before the current outbreak) and detected some form SARS-CoV-2-specific response in 19 of the samples. This could explain why a large proportion are only showing mild symptoms or are asymptomatic.
And as a counter to the ReACT study from Imperial College London (do they have any credibility left after their earlier predictions anyway?) saying there are 96,000 new infections in England alone and R is at 1.5 with cases doubling every 9 days (link: https://www.imperial.ac.uk/news/207534/coronavirus-infections-rising-rapidly-england-react/)
Tim Spector of Kings College, with the help of the Zoe app, have reported their latest findings with 43,000 new cases per day across the UK, R is at 1.1 and cases doubling every 28 days.
https://www.nature.com/articles/s41586-020-2550-z?flip=true
Short version: Brought to light by a recent video by Dr John Campbell, but a study published in July was showing people who were previously infected with the 2003 SARS virus are showing Memory T-Cell immunity 17 years after being infected with SARS-CoV-1 to SARS-CoV-2. They also tested 37 samples they had taken from uninfected people from 2019 (so before the current outbreak) and detected some form SARS-CoV-2-specific response in 19 of the samples. This could explain why a large proportion are only showing mild symptoms or are asymptomatic.
And as a counter to the ReACT study from Imperial College London (do they have any credibility left after their earlier predictions anyway?) saying there are 96,000 new infections in England alone and R is at 1.5 with cases doubling every 9 days (link: https://www.imperial.ac.uk/news/207534/coronavirus-infections-rising-rapidly-england-react/)
Tim Spector of Kings College, with the help of the Zoe app, have reported their latest findings with 43,000 new cases per day across the UK, R is at 1.1 and cases doubling every 28 days.
driller
my life my word
R number falls for 2nd week in a row
Now 1.1 to 1.3
Now 1.1 to 1.3
That’s an increase then isn’t it ?
macbeth
Dismembered
No I think that the OP meant that it has now fallen to between 1.1 and 1.3